What is the PHAT stock price?

Phathom Pharmaceuticals, Inc. (PHAT) last available close: $6.22, as of 10/29/26. Prices on Cylvex may be delayed.

How many analyst price targets for PHAT were reached?

2 of 9 published price targets for PHAT were reached within 12 months (22% reached); 13 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on PHAT?

10 firms have published price targets or ratings on PHAT that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

NASDAQ

Updated Oct 30, 9:29 AM ET

PHAT

Phathom Pharmaceuticals, Inc.

$6.21CS band Mixed

−$0.06 (0.96%) Thu · Closed $6.22

−$0.01 (0.13%) ☀ Pre-Market

Oct 30, 9:29 AM ET

About PHAT

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

News

2 latest

No direct coverage yet · Showing articles that mention PHAT

Mon, Oct 26

GlobeNewswire Inc.10/26/26

Phathom Pharmaceuticals Provides Update on FDA Litigation

Phathom Pharmaceuticals announced that the FDA established a public docket to solicit comments on regulatory questions regarding BDR Pharmaceuticals' challenge to VOQUEZNA's 10-year New Chemical Entity (NCE) exclusivity, which is set to expire May 3, 2032. Phathom plans to intervene in the litigation and submit comments to defend its statutory exclusivities. A second ANDA filer, Saba Ilac, has also indicated intent to consolidate its case with BDR's.

Fri, Oct 23

GlobeNewswire Inc.10/23/26

Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA

BDR Pharmaceuticals filed suit against the FDA challenging the agency's application of the GAIN Act to extend Phathom Pharmaceuticals' New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan) through May 2032. Phathom believes the FDA correctly evaluated the issue and intends to defend its statutory exclusivities.

Headlines open the publisher's site.